XML 84 R73.htm IDEA: XBRL DOCUMENT v3.21.2
Note 16 - Related Party Transactions (Details Textual)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 01, 2020
USD ($)
shares
Oct. 01, 2017
CAD ($)
Jan. 31, 2017
CAD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2020
USD ($)
Dec. 14, 2017
Dec. 02, 2017
Jul. 12, 2017
Notes Receivable, Related Parties, Current       $ 0   $ 0     $ 17,901      
Stock Issued During Period, Value, Issued for Settlement of Lease Termination         $ 50,700   $ 50,700          
Operating Lease, Right-of-Use Asset       150,323   150,323     0      
Operating Lease, Liability, Total       318,775   318,775            
Gain (Loss) on Termination of Lease           (0) (2,992)          
Lease Arrangement, 20 North Rear Road [Member]                        
Operating Lease, Monthly Rent     $ 4,000                  
Lessee, Operating Lease, Term of Contract (Year)     5 years                  
Stock Issued During Period, Shares, Issued for Settlement of Lease Termination (in shares) | shares 36,500                      
Stock Issued During Period, Value, Issued for Settlement of Lease Termination $ 50,700                      
Lessee, Operating Lease, Discount Rate 8.00%                      
Operating Lease, Right-of-Use Asset $ 48,110                      
Operating Lease, Liability, Total 45,118                      
Gain (Loss) on Termination of Lease $ (53,692)                      
Leases Office Space from R&D Labs Canada, Inc [Member]                        
Operating Lease, Monthly Rent   $ 2,608                    
Operating Lease, Liability, Total       $ 318,775   $ 318,775     164,997      
Operating Lease, Expense         2,982   20,391          
Long-term Convertible Notes Payable to Multiple Private Investors [Member]                        
Debt Instrument, Interest Rate, Stated Percentage                       5.00%
CEN Biotech Ukraine [Member] | XN Pharma [Member]                        
Ownership Percentage                   49.00%    
CEN Biotech Ukraine [Member]                        
Percentage of Related Party's Equity Interest Owned by Director                   25.50%    
Business Acquisition, Percentage of Voting Interests Acquired                   51.00%    
Emergence Global [Member]                        
Notes Receivable, Related Parties, Current                 17,901      
Joseph Byrne [Member]                        
Percentage of Related Party's Equity Interest Owned       5.00%   5.00%            
CEN Biotech Ukraine [Member]                        
Notes Receivable, Related Parties, Current                 17,901      
Due from Related Parties, Total       $ 1,299,328   $ 1,299,328     1,179,328      
Percentage of Related Party's Equity Interest Owned by Director                     51.00%  
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]                        
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings               $ 255,141        
Notes Receivable, Related Parties               44,859        
Board Members and Officers [Member] | Consulting Fees [Member]                        
Related Party Transaction, Amounts of Transaction       53,914 $ 31,200 131,914 $ 93,600          
Due to Related Parties, Total       $ 462,114   $ 462,114     $ 330,200      
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]                        
Notes Payable, Related Parties               $ 300,000